Journal
FRONTIERS IN ONCOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.894214
Keywords
NSCLC; RET fusion; targeted therapy; drug resistance; immunotherapy
Categories
Funding
- National Natural Science Foundation of China [81403220]
- National key research and development (RD) plan [2018YFC1707400]
- Tianjin Health and family planning-high level talent selection and training project
Ask authors/readers for more resources
Significant progress has been made in the treatment of driver gene-positive Non-Small Cell Lung Cancer (NSCLC) in recent years. RET fusion, which occurs in 0.7% to 2% of NSCLC cases, is associated with a younger age and never-smoker status. The use of pralsetinib and selpercatinib for RET fusion NSCLC is recommended according to the 2021 NSCLC treatment guidelines. This review summarizes the research progress, current challenges, and proposals for improving the outlook for patients with RET fusion NSCLC.
Great progress has been made in the treatment of driver gene-positive Non- Small Cell Lung Cancer (NSCLC) in recent years. RET fusion was seen in 0.7% to 2% of NSCLC and was associated with younger age and never-smoker status. The pralsetinib and selpercatinib for RET fusion NSCLC was recommended by the 2021 NSCLC treatment guidelines. This review outlines the research progress in the treatment of RET fusion NSCLC, identifies current challenges and describes proposals for improving the outlook for these patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
